Metformin improved insulin resistance regardless of baseline BMI in adolescents with type 1 diabetes.
Lower composite incidence of macrovascular events, lower incidence of coronary artery disease at 5 years
Lorcaserin reduces the risk for diabetes in obese or overweight patients with prediabetes or without diabetes and reduces HbA1c among those with diabetes.
HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.
Intensive blood pressure therapy is associated with a significantly lower risk for serious cardiovascular events in the adults with diabetes.
Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
Racial/ethnic differences were seen in the association of aldosterone with incident type 2 diabetes.
No benefit in healthy elderly patients; the protective effect is limited to those with type 2 diabetes aged 75 to 84 years.
WHO has also made recommendations for type of insulin for type 1 and type 2 diabetes in low-resource settings.
Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.
The substantial burden of cardiovascular disease in patients with diabetes has led to the exploration of various cardiovascular disease prevention strategies, including the use of aspirin.
Up-titration to a high-intensity statin occurred in only 37.7% of patients with diabetes after an acute myocardial infarction.
The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.
Investigators sought to compare cardiovascular risk and disease prevalence in the Hispanic and Latina population in the United States with and without a history of gestational diabetes.
While certain biomarkers are associated with eGFR decline in patients with type 2 diabetes, their predictive power is low.
Investigators examined the relationship between HbA1c with cardiovascular disease and it's subtypes.
Little or no excess risk of death, MI, or stroke in patients with type 2 diabetes who had their 5 risk factor variables within target ranges.
However, the temporary increase in type 2 diabetes risk does not attenuate benefits on total and CVD mortality.
Glucose concentration assessment before noncardiac surgery may help clinicians predict the risk for postoperative myocardial injury in patients with and without diabetes.
Diagnostic thresholds for gestational diabetes should be adapted using local populations.
A full-nut dose lowered HbA1c and estimated cholesterol levels in LDL particles of a certain diameter.
This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.
Small changes in health behaviors were seen in partners of those newly diagnosed with diabetes.
Increased risk for heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction.
Investigators examined the outcomes of using various beta-blockers in patients with type 2 diabetes after a myocardial infarction.
Canagliflozin vs other SGLT2 inhibitors and non-SLGT2 inhibitors were examined for the risk for heart failure-related hospitalization and below the knee amputation.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
Women with preeclampsia or gestational hypertension during their first pregnancy were more likely to report increased rates of subsequent chronic hypertension, type 2 diabetes, and hypercholesterolemia compared with women who were normotensive.
The Cardiology Advisor Articles
- Class 1 Device Recall: Endologix AFX Device Recalled Due to Type III Endoleaks
- Harvard: Fraudulent Data Found in Publications of Heart Researcher
- Traumatic Life Events May Increase Risk for Atrial Fibrillation in Older Women
- No Differences Between Bivalirudin, UFH Post-PCI After Ticagrelor Pretreatment
- Rivaroxaban Approved to Reduce Risk of Major Cardiovascular Events in CAD, PAD
- Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy
- Long-Term Exposure to Elevated BP Associated With AS and AR
- Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population
- Takotsubo Syndrome Associated With Substantial Morbidity, Mortality
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes
- Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials
- Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis
- Can Dermatoscope Magnets Be Used With CV Implanted Electronic Devices?
- The Striking Effects of Diversity in Health Care: Improving Patient Outcomes